Unisound AI Technology Co., Ltd. – Key Management Significantly Increase H Shareholdings, Demonstrating Strong Confidence in Company Prospects
Summary of Key Points
- Controlling shareholder, Executive Director and CEO Dr. Huang Wei, and Executive Director Dr. Liu Shengping, have both increased their personal shareholdings in Unisound AI Technology Co., Ltd. (stock code: 9678) by acquiring H Shares on the open market.
- Dr. Huang Wei purchased a total of 56,000 H Shares between July 6, 2026 and July 16, 2026, with a total consideration of HK\$3,979,255.90.
- Dr. Liu Shengping purchased a total of 15,140 H Shares between July 7, 2026 and July 16, 2026, with a total consideration of HK\$1,125,933.00.
- Dr. Huang Wei has indicated plans for further shareholding increase, subject to market conditions and in full compliance with relevant regulations.
- No controlling shareholders have reduced their equity interests since listing; the controlling group now collectively holds approximately 31.61% of the company.
Details of Shareholding Increases
Unisound AI Technology Co., Ltd. (“the Company”) has announced that two of its top executives have made significant purchases of the Company’s H Shares on the open market in July 2026:
- Dr. Huang Wei (controlling shareholder, executive director, and CEO) acquired 56,000 H Shares between July 6 and July 16, 2026, at a total cost of HK\$3,979,255.90. After this transaction, Dr. Huang directly holds 56,000 H Shares and, through controlled entities (Yunsi Shangyi and Yunchuang Hudong), is deemed interested in a further 19,349,872 Shares (5,804,961 H Shares and 13,544,911 Domestic Unlisted Shares), bringing his aggregate interest to 19,405,872 Shares, or approximately 25.99% of the total issued shares of the Company.
- Dr. Liu Shengping (executive director) acquired 15,140 H Shares between July 7 and July 16, 2026, with an aggregate consideration of HK\$1,125,933.00. He now directly holds 15,140 H Shares, representing approximately 0.02% of the Company’s total issued shares.
These purchases are personal investments by Dr. Huang and Dr. Liu and are intended as a demonstration of their confidence in the company’s future prospects and growth potential.
Potential for Further Shareholding Increases
Notably, Dr. Huang Wei has indicated his intention to further increase his shareholding in the Company’s H Shares on the open market in the future, subject to market conditions and in accordance with all applicable laws and regulations. Importantly, he has confirmed that any further increase will be structured to avoid triggering a mandatory general offer under Rule 26 of the Codes on Takeovers and Mergers and Share Buy-backs.
Shareholding Structure and Stability
As of the announcement date, Unisound AI Technology’s total issued shares stood at 74,675,593, comprising 24,995,061 Domestic Unlisted Shares, 4,570,649 Unlisted Foreign Shares, and 45,109,883 H Shares.
Following the recent acquisitions, the main controlling group (Dr. Huang Wei, Dr. Liang Jia’en, and Dr. Kang Heng, acting in concert) collectively holds 23,601,661 shares (16,481,964 Domestic Unlisted Shares and 7,119,697 H Shares), representing 31.61% of the total issued shares. The Company also confirmed that none of the controlling shareholders have reduced their equity interests since listing, a signal of long-term commitment and stability that may be reassuring for investors.
Implications for Investors
- Insider Confidence: The increase in personal shareholding by the Company’s most senior management is a strong signal of their confidence in Unisound AI Technology’s business outlook and growth trajectory.
- Potential Share Price Impact: Management share purchases are often interpreted positively by the market and may lead to increased investor interest and potential share price appreciation.
- Further Purchases Possible: Dr. Huang’s stated intention to make further purchases may provide additional support to the stock price in the future.
- Stable Controlling Interest: The confirmation that no controlling shareholder has sold shares since listing, and that the controlling group retains a significant stake, further underlines management’s alignment with shareholder interests.
- Regulatory Compliance: All transactions are being conducted in compliance with relevant regulations, with careful structuring to avoid triggering mandatory tender offers.
Cautionary Note
Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company, as future share purchases by management may depend on market conditions and are not guaranteed.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors should make their own decisions based on their individual circumstances and consult with their professional advisors before making any investment decisions. The information above is based on a company announcement as of July 23, 2026. Market conditions may change, and the forward-looking statements in this article are subject to risks and uncertainties.
